Profile data is unavailable for this security.
About the company
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. The Company leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins and small molecule therapeutics to potentially treat and prevent a diverse array of diseases.
- Revenue in USD (TTM)27.15m
- Net income in USD-27.95m
- Incorporated2007
- Employees101.00
- LocationCapricor Therapeutics Inc10865 Road to the Cure, Suite 150SAN DIEGO 92121United StatesUSA
- Phone+1 (858) 727-1755
- Fax+1 (302) 655-5049
- Websitehttps://capricor.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P3 Health Partners Inc | 1.40bn | -69.48m | 153.82m | 400.00 | -- | 0.4169 | -- | 0.1097 | -0.5821 | -0.5821 | 11.56 | 1.03 | 1.56 | -- | 10.97 | 3,507,143.00 | -20.51 | -- | -110.70 | -- | 0.6223 | 0.1781 | -13.17 | -56.93 | -- | -9.67 | 0.2686 | -- | 20.67 | 70.58 | 78.61 | -- | -11.20 | -- |
| Adverum Biotechnologies Inc | 0.00 | -99.86m | 155.80m | 121.00 | -- | 0.9272 | -- | -- | -7.99 | -7.99 | 0.00 | 8.08 | 0.00 | -- | -- | 0.00 | -40.33 | -36.39 | -46.64 | -39.04 | -- | -- | -- | -5,279.60 | -- | -- | 0.00 | -- | -- | 17.43 | 24.18 | -- | -0.0247 | -- |
| Achieve Life Sciences Inc | 0.00 | -27.54m | 157.97m | 22.00 | -- | 3.74 | -- | -- | -1.10 | -1.10 | 0.00 | 1.23 | 0.00 | -- | -- | 0.00 | -58.78 | -86.31 | -71.94 | -119.59 | -- | -- | -- | -- | -- | -11.79 | 0.294 | -- | -- | -- | 29.60 | -- | -14.51 | -- |
| Ventyx Biosciences Inc | 0.00 | -171.30m | 162.54m | 73.00 | -- | 0.5788 | -- | -- | -2.79 | -2.79 | 0.00 | 3.97 | 0.00 | -- | -- | 0.00 | -52.07 | -- | -55.27 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.97 | -- | -- | -- |
| Capricor Therapeutics Inc | 27.15m | -27.95m | 164.32m | 101.00 | -- | 14.04 | -- | 6.05 | -0.9302 | -0.9302 | 0.9072 | 0.3596 | 0.6443 | -- | 59.18 | 268,833.90 | -66.31 | -54.12 | -208.71 | -75.13 | -- | -- | -102.93 | -316.25 | -- | -- | 0.2269 | -- | 886.81 | 72.02 | 23.20 | -- | 45.27 | -- |
| Immunic Inc | 0.00 | -95.31m | 164.84m | 77.00 | -- | 2.59 | -- | -- | -1.51 | -1.51 | 0.00 | 0.7058 | 0.00 | -- | -- | 0.00 | -108.78 | -72.09 | -141.92 | -80.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.25 | -- | -10.97 | -- |
| Tenaya Therapeutics Inc | 0.00 | -120.74m | 168.03m | 140.00 | -- | 1.25 | -- | -- | -1.54 | -1.54 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -62.89 | -- | -69.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.3388 | -- | -- | -- |
| Inovio Pharmaceuticals Inc | 591.86k | -121.64m | 168.25m | 122.00 | -- | 1.74 | -- | 284.27 | -5.11 | -5.11 | 0.0248 | 3.73 | 0.0032 | -- | 0.6652 | 4,851.31 | -66.32 | -59.52 | -84.33 | -71.29 | -- | -- | -20,552.24 | -4,097.36 | -- | -- | 0.00 | -- | -91.89 | -51.33 | 51.71 | -- | -31.22 | -- |
| Context Therapeutics Inc | 0.00 | -18.57m | 169.50m | 5.00 | -- | 1.68 | -- | -- | -1.06 | -1.06 | 0.00 | 1.35 | 0.00 | -- | -- | 0.00 | -28.46 | -- | -29.68 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -61.53 | -- | -- | -- |
| Seres Therapeutics Inc | 374.00k | -162.11m | 172.19m | 233.00 | -- | -- | -- | 460.40 | -1.18 | -1.18 | 0.0027 | -0.5742 | 0.001 | -- | 0.0286 | 1,605.15 | -44.53 | -41.51 | -59.82 | -54.13 | -- | -- | -43,343.58 | -170.14 | 0.889 | -17.64 | 6.65 | -- | 1,672.24 | 34.91 | 54.54 | -- | 32.72 | -- |
| Galectin Therapeutics Inc | 0.00 | -48.03m | 172.51m | 14.00 | -- | -- | -- | -- | -0.7831 | -0.7831 | 0.00 | -1.32 | 0.00 | -- | -- | 0.00 | -185.54 | -92.08 | -382.33 | -121.97 | -- | -- | -- | -- | -- | -8.59 | 8.29 | -- | -- | -- | -15.26 | -- | -- | -- |
| DiaMedica Therapeutics Inc | 0.00 | -19.90m | 176.55m | 18.00 | -- | 3.30 | -- | -- | -0.5238 | -0.5238 | 0.00 | 1.25 | 0.00 | -- | -- | 0.00 | -33.49 | -45.38 | -34.98 | -48.24 | -- | -- | -- | -- | -- | -- | 0.0006 | -- | -- | -- | -41.72 | -- | -13.65 | -- |
| Lineage Cell Therapeutics Inc | 6.19m | -24.19m | 177.51m | 75.00 | -- | 2.60 | -- | 28.69 | -0.1342 | -0.1342 | 0.0343 | 0.3617 | 0.0577 | -- | 18.25 | 82,480.00 | -22.57 | -19.53 | -26.03 | -22.59 | 90.83 | 89.13 | -391.25 | -370.88 | -- | -- | 0.0017 | -- | -39.16 | 12.39 | 18.22 | -- | -27.16 | -- |
Data as of Sep 20 2024. Currency figures normalised to Capricor Therapeutics Inc's reporting currency: US Dollar USD
15.75%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2024 | 1.50m | 4.62% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 1.50m | 4.60% |
| Geode Capital Management LLCas of 30 Jun 2024 | 641.57k | 1.97% |
| Millennium Management LLCas of 30 Jun 2024 | 479.51k | 1.47% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 401.02k | 1.23% |
| American Portfolios Advisors, Inc.as of 30 Jun 2024 | 161.20k | 0.50% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 137.50k | 0.42% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 2024 | 129.61k | 0.40% |
| Marshall Wace LLPas of 30 Jun 2024 | 89.31k | 0.27% |
| AHL Partners LLPas of 30 Jun 2024 | 84.65k | 0.26% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
